Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Retrospective Clinical Records Review of Patients Diagnosed With Gastrointestinal Stromal Tumour at Two Tertiary Institutes in Singapore

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2008 by National University Hospital, Singapore.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National University Hospital, Singapore
ClinicalTrials.gov Identifier:
NCT00718211
First received: July 15, 2008
Last updated: July 18, 2008
Last verified: July 2008
  Purpose

To review the characteristics and treatment of gastrointestinal tumours at the two tertiary centres in Singapore


Condition
Gastrointestinal Stromal Tumors

Study Type: Observational
Official Title: A Retrospective Clinical Records Review of Patients Diagnosed With Gastrointestinal Stromal Tumour at Two Tertiary Institutes in Singapore.

Resource links provided by NLM:


Further study details as provided by National University Hospital, Singapore:

Study Start Date: May 2006
Detailed Description:

A retrospective clinical records review of patients diagnosed with gastrointestinal stromal tumour (GIST) in the two tertiary centres in Singapore i.e. Singapore General Hospital and National University Hospital.

Gastrointestinal tumours are the most common soft-tissue tumours of the gastrointestinal tracts. Remarkable progress has been made during the last several years in the diagnosis and treatment of GIST. Understanding of the molecular pathogenesis of GIST which is linked to deregulated KIT tyrosine-kinase activity has improved diagnosis, such that GIST is now more frequently and specifically identified. More importantly, systemic tyrosine kinase inhibitor, imatinib, has been used successfully in the treatment of GIST patients with advanced or unresectable disease.

GIST has been reviewed in the Western literature but there is a lack of Asian data. The review will help us to better understand the disease in our population.Furthermore we will also examine several unresolved issues in the Western literature by looking into our local data. These include required duration of imatinib therapy, role of imatinib in the adjuvant setting (application of chemotherapy after macroscopically complete removal of tumour) and role of combination therapies.

The medical records of all patients diagnosed with the disease at the two centres will be reviewed.

Analysis of the results aims to:

  1. to compare the characteristics of the GIST (epidemiology, site, morphology, immunohistochemistry profile) in our centres compared to the well-published literature.
  2. to compare the treatment regimen and results of our centres compared to others
  3. to review the role of chemotherapy in the adjuvant settings in the centres.
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

To review medical records of all patients diagnosed with the disease at the two specified centres.

The medical records will be obtained through both paper and electronic medical systems.

All data will be contained in a password secured database and will be securely located behind institutional firewalls.

Criteria

Inclusion Criteria:

  • Patients diagnosed with Gastrointestinal stromal tumor.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00718211

Contacts
Contact: Ross Andrew Soo, MBBS 65-6772-4624 Ross_Soo@nuh.com.sg

Locations
Singapore
National University Hospital Recruiting
Singapore, Singapore
Contact: Ross Andrew Soo, MBBS    65-6772-4624    Ross_Soo@nuh.com.sg   
Principal Investigator: Ross Andrew Soo, MBBS         
Sponsors and Collaborators
National University Hospital, Singapore
Investigators
Principal Investigator: Ross Andrew Soo, MBBS National University Hospital, Singapore
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00718211     History of Changes
Other Study ID Numbers: GA01/12/06
Study First Received: July 15, 2008
Last Updated: July 18, 2008
Health Authority: Singapore: Domain Specific Review Boards

Additional relevant MeSH terms:
Gastrointestinal Stromal Tumors
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue

ClinicalTrials.gov processed this record on November 19, 2014